Objective:

To investigate the association between pulse pressure (PP) and the progression of cardiometabolic diseases (CMDs), cardiometabolic multimorbidity (CMM), and all-cause mortality.

Approach:

Key Findings:

• Per 1-SD increase in PP, there was a significant association with transitions from health to CMD (HR = 1.13, 95% CI: 1.12–1.14) and to CMM (HR = 1.18, 95% CI: 1.15–1.21).
• Q4 versus Q1 comparisons indicated a 36% higher risk for both CMD and CMM outcomes.
• The PP–CMM association was strongest among patients with stroke (HR = 1.23, 95% CI: 1.11–1.36) and in participants aged < 60 years, women, and those with BMI 18.5 ≤ 25 kg/m2.
• Threshold-effect analyses identified specific risk turning points: 40 mmHg for CMD, 42 mmHg for mortality, and 52 mmHg for CMM development.

Interpretation:

Elevated pulse pressure is significantly associated with increased risks of cardiometabolic disease progression and mortality.

Limitations:

• The study may not account for all potential confounding factors influencing the associations.
• Findings are based on a specific cohort from the UK Biobank, which may limit generalizability.

Conclusion:

Elevated pulse pressure is linked to higher risks of CMD progression and mortality.

Source

Based on findings from:

Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank

Ting Lin, Shuai Hu, Wen Gong, Linqi Li, Zhaowei Zhu, Hebin Xie, Feijun Zhao. Frontiers In Cardiovascular Medicine, 2026.

https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1829003/full

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.